Sage Therapeutics, Inc.
SAGE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $41,243 | $86,455 | $7,686 | $6,308 |
| % Growth | -52.3% | 1,024.8% | 21.8% | – |
| Cost of Goods Sold | $9,444 | $2,159 | $813 | $553 |
| Gross Profit | $31,799 | $84,296 | $6,873 | $5,755 |
| % Margin | 77.1% | 97.5% | 89.4% | 91.2% |
| R&D Expenses | $225,895 | $356,235 | $326,163 | $283,166 |
| G&A Expenses | $216,420 | $274,524 | $227,699 | $183,498 |
| SG&A Expenses | $216,420 | $274,524 | $227,699 | $183,498 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $21,854 | $33,386 | $15 | $134 |
| Operating Expenses | $464,169 | $630,759 | $553,862 | $466,664 |
| Operating Income | -$432,370 | -$579,849 | -$546,989 | -$460,909 |
| % Margin | -1,048.3% | -670.7% | -7,116.7% | -7,306.7% |
| Other Income/Exp. Net | $31,704 | $38,360 | $14,205 | $3,017 |
| Pre-Tax Income | -$400,666 | -$541,489 | -$532,784 | -$457,892 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$400,666 | -$541,489 | -$503,267 | -$450,827 |
| % Margin | -971.5% | -626.3% | -6,547.8% | -7,146.9% |
| EPS | -6.59 | -9.05 | -8.49 | -7.68 |
| % Growth | 27.2% | -6.6% | -10.5% | – |
| EPS Diluted | -6.59 | -9.05 | -8.49 | -7.68 |
| Weighted Avg Shares Out | 60,766 | 59,836 | 59,306 | 58,670 |
| Weighted Avg Shares Out Dil | 60,766 | 59,836 | 59,306 | 58,670 |
| Supplemental Information | – | – | – | – |
| Interest Income | $31,675 | $38,743 | $14,190 | $2,883 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1,031 | $1,393 | $1,122 | $4,182 |
| EBITDA | -$409,485 | -$545,070 | -$545,867 | -$456,727 |
| % Margin | -992.9% | -630.5% | -7,102.1% | -7,240.4% |